Results for tag: "Breast Cancer Monoclonal Antibodies"

In the realm of biotechnology, the breast cancer monoclonal antibodies market encompasses various therapies developed to target specific antigens found on the surface of cancer cells. Monoclonal antibodies (mAbs) are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. MAbs are designed to bind to antigens that are generally more numerous on the surface of cancer cells than on the cells of normal tissue, which helps in targeting the tumor without affecting healthy tissue. Certain monoclonal antibodies may be conjugated with chemotherapy drugs or radioactive substances to deliver targeted therapy directly to the cancer cells. MAbs used in breast cancer treatment are part of a broader class of biologics known as targeted therapies which have revolutionized treatment protocols due to their precision and ability to complement traditional treatments like chemotherapy and radiation. Some notable enterprises involved in the breast cancer monoclonal antibodies market include Roche Holding AG, which produces several widely used breast cancer mAbs; AstraZeneca, which collaborates with Daiichi Sankyo on developing and commercializing new therapies; Pfizer Inc., with its contributions to targeted breast cancer treatments; Amgen, focusing on innovative oncology drugs; and Merck & Co., which has a strong presence in the oncology field, including treatments for breast cancer. Show Less Read more